10 most-read supply chain stories in September

An oncology drug trial halted after a patient death most captured the attention of readers in September.

Advertisement

Here are the 10 most-read supply chain stories for September, starting with the most popular.

1. Patient death spurs FDA to halt cancer drug trials

2. Amazon in talks with PBMs over pharma supply chain

3. FDA: Major drug shortages possible after Hurricane Maria

4. 6 FDA decisions to look for in September

5. How this movie studio is challenging blood draw restrictions

6. Cleveland Clinic’s 5-step strategy to address rising drug prices

7. Supply chain inefficiencies leave $23B in potential savings on the table for hospitals

8. FDA calls out EpiPen manufacturer for product flaws linked to patient deaths

9. Hurricane Maria stalls shipments of Baxter’s IV products to US hospitals

10. Express Scripts CMO: Healthcare system isn’t set up to pay for Novartis’ $475k cancer drug

More articles on supply chain:

US Army delivers 3-day fuel supply to Puerto Rican children’s hospital
Rite Aid names former Walgreens executive as president, COO
5 drug, devicemakers in the headlines

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.